📰 Head External News
Head External News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Head External. Real-time updates on events, politics, business and more.
March 15, 2022
Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolerability data with vamorolone
March 15, 2022
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement...
March 15, 2022
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland
March 15, 2022
Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference  Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolera...
March 11, 2022
Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing
March 11, 2022
Santhera Pharmaceuticals (SIX: SANN) announces preliminary 2021 financial results and operational progress made. The Company is on track to start a rolling NDA submission for vamorolone in DMD at the end of March. With a cash balance of CHF 18 million (February 28, 2022), the announced increase of share issuances ...
March 11, 2022
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Initiation of rolling
March 2, 2022
Santhera Signs Gene Therapy Agreement with SEAL Therapeutics Pratteln, Switzerland, February 28, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an agreement with SEAL Therapeutics for a gene therapy approach targeting congenital muscular dystrophy.  Santhera has entered into an...
February 28, 2022
Pratteln, Switzerland, February 28, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces the signing of an agreement with SEAL Therapeutics for a gene therapy approach targeting congenital muscular dystrophy.
February 18, 2022
Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Completes Repayment of 2017/22 Convertible Bonds